NCT03708133View on ClinicalTrials.gov

Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

April 17, 2019

Study Completion Date

June 18, 2019

Conditions
Bioequivalence
Interventions
DRUG

Nifurtimox (Lampit, BAYA2502)_Test

Orally intake of 1 \*120mg new formulation tablet as test treatment

DRUG

Nifurtimox (Lampit, BAYA2502)_Reference

Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment

Trial Locations (1)

C1425BAB

FP Clinical Pharma, Buenos Aires

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY